Article

Intense pulsed light therapy aids in dry eye

Results of a study designed to investigate the addition of microdermabrasion to intense pulsed light therapy in patients with meibomian gland dysfunction and dry eye syndrome corroborate the efficacy of IPL for increasing tear breakup time and decreasing dry eye symptoms but fail to confirm the hypothesis that the benefits of IPL may be enhanced by microdermabrasion, according to Rolando Toyos, MD.

In a previous study supported by an ASCRS research grant, Dr. Toyos used IPL to treat 100 patients with MGD and dry eye syndrome who remained symptomatic despite use of many prior therapies. They received IPL at four sessions spaced 4 to 6 weeks apart with the treatment area encompassing the midface from the tragus to the nose bilaterally. The results showed TBUT increased significantly from baseline, and there were also symptomatic improvements measured by responses to a subjective questionnaire.

The study of adjunctive dermabrasion enrolled 15 patients with MGD and symptomatic dry eye who had a TBUT <6 seconds. The patients again underwent IPL across the entire midface, but microdermabrasion was performed on one side only prior to IPL. Patients were treated until symptoms resolved, for total of two to four treatments.

"While this study failed to find a benefit for adding microdermabrasion to IPL, it was a small pilot trial and there is reasonable scientific rationale supporting the combination technique," said Dr. Toyos, medical director, Toyos Clinic, Memphis, TN. "Therefore, further study seems warranted."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.